Menlo Therapeutics has begun patient enrolment in the second of two Phase lll trials of serlopitant for the treatment of pruritus with prurigo nodularis (PN).
The multi-centre, randomised, double-blind, placebo-controlled trial is being conducted in Europe.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial aims to determine whether the 5mg daily dose of serlopitant, administered for ten weeks, can minimise pruritus associated with PN compared with placebo.
It is expected to enrol nearly 200 patients with a worst-itch NRS score, or WI-NRS, of at least seven at screening at around 50 sites.
The trial’s primary efficacy endpoint is a four-point responder rate in the WI-NRS at ten weeks.
Results from the trial are expected to be available in the first half of 2020.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMenlo Therapeutics is currently conducting the first of two PN Phase lll trials in the US.
The trial, which started enrolling patients in May this year, features a similar design to the second PN Phase lll trial.
In addition, Menlo Therapeutics completed a Phase ll clinical trial of serlopitant in patients with PN in June 2016.
Germany’s University Hospital Münster Department of Dermatology Center for Chronic Pruritus representative Dr Sonja Ständer recently presented a new exploratory analysis of additional data from the Phase ll trial.
Ständer said: “Limited data are available about disease characteristics for patients with prurigo nodularis. The Phase ll trial of serlopitant was one of the largest randomised controlled trials conducted to date in this patient population, and we wanted to conduct a retrospective analysis to better understand the sensory experience of patients with PN and the impact of treatment on these sensations.
“The most common descriptions of pruritus reported by these patients at baseline were itching, combined with pain-related sensations such as burning and stinging.
“In this retrospective analysis, we observed improvement in some of the most common pruritus characteristics reported by the patients in this study when treated with serlopitant for eight weeks.”
Pruritus or itch is a sensation that leads to the desire or reflex to scratch.
